PIK3CA Mutations Blunt Benefit of Anti-HER2 Drugs
Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations
Important new data from two trials evaluating different treatment approaches in metastatic colorectal cancer provide reassurance for clinicians that current treatment choices are valid, and confirm that molecular characterisation of such tumours is vital
Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer; HER2 inhibition shows promise in HER2-positive non-small cell lung cancer
Preliminary data from a phase III trial suggest drug is well tolerated and leads to a sustained response in patients who have progressed after ipilimumab therapy
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target
Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.
Experts are divided on the value of lung cancer vaccination after disappointing results from the MAGRIT phase III trial.
Treatments for advanced cancer are often unavailable or available only at substantial out of pocket cost in many Eastern European countries compared to those in Western Europe
Dual targeting with pertuzumab and trastuzumab plus chemotherapy has become the new standard therapy in metastatic HER2 positive breast cancer
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them
New initiative aims to promote exchange of ideas among female oncologists and support women with cancer in Greece
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.